论文部分内容阅读
目的探讨肠道菌群调节剂(培菲康)辅助治疗小儿反复呼吸道感染(RRI)的疗效,及其对T细胞亚群的影响。方法选择96例反复呼吸道感染的患儿,随机将患儿分为两组,两组患儿急性期均给予常规治疗,治疗组在对照组常规治疗的基础上,加服培菲康,疗程为6个月。两组患儿均随访12个月,记录呼吸道感染情况、T细胞亚群(CD3、CD4、CD8)检测结果及不良反应。结果治疗组、对照组总有效率分别为91.3%、73.3%,总有效率比较差异有统计学意义(P<0.05)。治疗组的呼吸道感染次数(t=9.09),发热天数(t=7.22)、咳嗽天数(t=7.58)均少于对照组,差异有统计学意义(P均<0.01);治疗组在治疗后的CD3、CD4、CD4/CD8比值均升高(P均<0.01),CD8降低(P<0.01);对照组用药前、后CD3、CD4、CD8、CD4/CD8之值无显著性差异(P>0.05)。结论培菲康对反复呼吸道感染患儿有免疫调节作用,对反复呼吸道感染急性发作可起到一定的预防作用。
Objective To investigate the curative effect of adjuvant intestinal flora modifier (Peifu Kang) on children with recurrent respiratory tract infection (RRI) and its effect on T cell subsets. Methods Ninety-six children with recurrent respiratory tract infection were randomly divided into two groups. The children in both groups were given routine treatment in the acute phase. The treatment group was treated with Pefikon on the basis of the routine treatment in the control group. The course of treatment was 6 months. The children in both groups were followed up for 12 months and the respiratory tract infection status, T cell subsets (CD3, CD4, CD8) test results and adverse reactions were recorded. Results The total effective rates of the treatment group and the control group were 91.3% and 73.3%, respectively. The total effective rate was significantly different (P <0.05). The number of respiratory tract infections (t = 9.09), days of fever (t = 7.22) and days of cough (t = 7.58) in the treatment group were all less than those in the control group (all P <0.01) (P <0.01), while CD8 decreased (P <0.01). There was no significant difference in the levels of CD3, CD4, CD4 / CD8 between the two groups > 0.05). Conclusion Pefikan has immunomodulatory effects on children with recurrent respiratory tract infections, and may play a preventive role in the acute episodes of recurrent respiratory infections.